Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco
Klotho Neurosciences (NASDAQ: KLTO), a biotechnology company developing cell and gene therapies for ALS, Alzheimer's, and Parkinson's disease, will present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco. The presentation is scheduled for January 14, 2025, at 3:00 PM PT at the Hilton San Francisco Union Square.
CEO Dr. Joseph Sinkule will discuss the company's work with the secreted form of the Klotho anti-aging gene ('s-KL'), their patent-protected development platform. The company aims to increase awareness of this 'master gene' and its potential role in treating neurodegenerative diseases. They are progressing toward clinical trials for ALS and seeking development partnerships for Alzheimer's and Parkinson's treatments.
KLTO has secured exclusive worldwide licenses from UAB and ICREA in Spain, with patents issued in the USA, Europe, and China for their therapeutic approach using s-KL to treat cognitive and behavioral impairments.
Klotho Neurosciences (NASDAQ: KLTO), un'azienda biotech che sviluppa terapie cellulari e geniche per ALS, Alzheimer e il morbo di Parkinson, presenterà al Biotech Showcase 2025 durante la J.P. Morgan Healthcare Week a San Francisco. La presentazione è programmata per il 14 gennaio 2025, alle 15:00 PT presso il Hilton San Francisco Union Square.
Il CEO Dr. Joseph Sinkule discuterà del lavoro dell'azienda con la forma segreta del gene anti-invecchiamento Klotho ('s-KL'), la loro piattaforma di sviluppo protetta da brevetto. L'azienda mira ad aumentare la consapevolezza di questo 'gene maestro' e del suo potenziale ruolo nel trattamento delle malattie neurodegenerative. Stanno procedendo verso studi clinici per l'ALS e cercano partnership per lo sviluppo di trattamenti per l'Alzheimer e il Parkinson.
KLTO ha ottenuto licenze esclusive a livello mondiale da UAB e ICREA in Spagna, con brevetti rilasciati negli USA, in Europa e in Cina per il loro approccio terapeutico che utilizza s-KL per trattare le disabilità cognitive e comportamentali.
Klotho Neurosciences (NASDAQ: KLTO), una empresa de biotecnología que desarrolla terapias celulares y génicas para ELA, Alzheimer y la enfermedad de Parkinson, presentará en el Biotech Showcase 2025 durante la J.P. Morgan Healthcare Week en San Francisco. La presentación está programada para el 14 de enero de 2025, a las 3:00 PM PT en el Hilton San Francisco Union Square.
El CEO Dr. Joseph Sinkule discutirá el trabajo de la empresa con la forma secretada del gen anti-envejecimiento Klotho ('s-KL'), su plataforma de desarrollo protegida por patente. La empresa busca aumentar la concienciación sobre este 'gen maestro' y su posible papel en el tratamiento de enfermedades neurodegenerativas. Están avanzando hacia ensayos clínicos para la ELA y buscando asociaciones de desarrollo para tratamientos de Alzheimer y Parkinson.
KLTO ha asegurado licencias exclusivas a nivel mundial de UAB e ICREA en España, con patentes emitidas en EE.UU., Europa y China para su enfoque terapéutico que utiliza s-KL para tratar las disfunciones cognitivas y del comportamiento.
클로토 뉴로사이언스(KNASDAQ: KLTO), ALS, 알츠하이머 및 파킨슨병을 위한 세포 및 유전자 치료제를 개발하는 생명공학 기업이 Biotech Showcase 2025에서 J.P. 모건 헬스케어 주간 동안 샌프란시스코에서 발표할 예정이다. 발표는 2025년 1월 14일 오후 3시 PT에 샌프란시스코 유니온 스퀘어 힐튼 호텔에서 예정되어 있다.
CEO인 조셉 싱쿨 박사는 클로토 항노화 유전자('s-KL')의 분비형에 대한 회사의 연구를 논의할 예정이다. 이들은 이 '주 유전자'와 신경퇴행성 질환 치료에서의 잠재적 역할에 대한 인식을 높이려 하고 있다. 이들은 ALS에 대한 임상 시험을 진행 중이며 알츠하이머 및 파킨슨 치료를 위한 개발 파트너십을 모색하고 있다.
KLTO는 스페인에 있는 UAB와 ICREA로부터 세계적인 독점 라이센스를 확보했으며, s-KL을 사용한 치료 접근법에 대해 미국, 유럽, 중국에서 특허를 보유하고 있다.
Klotho Neurosciences (NASDAQ: KLTO), une entreprise de biotechnologie développant des thérapies cellulaires et géniques pour la SLA, Alzheimer et la maladie de Parkinson, présentera au Biotech Showcase 2025 pendant la J.P. Morgan Healthcare Week à San Francisco. La présentation est prévue pour le 14 janvier 2025, à 15h00 PT au Hilton San Francisco Union Square.
Le PDG Dr. Joseph Sinkule discutera du travail de l'entreprise avec la forme sécrétée du gène anti-vieillissement Klotho ('s-KL'), leur plateforme de développement protégée par un brevet. L'entreprise vise à sensibiliser le public sur ce 'gène maître' et son rôle potentiel dans le traitement des maladies neurodégénératives. Ils avancent vers des essais cliniques pour la SLA et recherchent des partenariats de développement pour des traitements d'Alzheimer et de Parkinson.
KLTO a sécurisé des licences exclusives à l'échelle mondiale de la part de l'UAB et de l'ICREA en Espagne, avec des brevets délivrés aux États-Unis, en Europe et en Chine pour leur approche thérapeutique utilisant s-KL pour traiter les troubles cognitifs et comportementaux.
Klotho Neurosciences (NASDAQ: KLTO), ein Biotechnologieunternehmen, das Zell- und Gentherapien für ALS, Alzheimer und Parkinson entwickelt, wird beim Biotech Showcase 2025 während der J.P. Morgan Healthcare Week in San Francisco präsentieren. Die Präsentation ist für den 14. Januar 2025, um 15:00 Uhr PT im Hilton San Francisco Union Square geplant.
CEO Dr. Joseph Sinkule wird die Arbeit des Unternehmens mit der sekretorischen Form des Klotho-Anti-Aging-Gens ('s-KL') besprechen, ihrer patentgeschützten Entwicklungsplattform. Das Unternehmen hat sich zum Ziel gesetzt, das Bewusstsein für dieses 'Meistergen' und seine potenzielle Rolle bei der Behandlung neurodegenerativer Erkrankungen zu erhöhen. Sie machen Fortschritte in Richtung klinischer Studien für ALS und suchen Entwicklungspartnerschaften für Behandlungen von Alzheimer und Parkinson.
KLTO hat sich weltweite Exklusivrechte von UAB und ICREA in Spanien gesichert, mit Patenten, die in den USA, Europa und China für ihren therapeutischen Ansatz zur Behandlung kognitiver und verhaltensbedingter Beeinträchtigungen erteilt wurden, bei dem s-KL eingesetzt wird.
- None.
- None.
Company to present at 3:00 p.m. PT on Tuesday, January 14, at the Hilton San Francisco Union Square
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer’s, and Parkinson’s disease, announces that it will present at Biotech Showcase 2025, an event expected to include over 3,200 healthcare professionals with more than 1,200 investors. The event will be held at the Hilton Hotel in Union Square, San Francisco during the J.P. Morgan Healthcare Week, and KLTO’s Founder, CEO and Chairman, Dr. Joseph Sinkule, will give a presentation at 3:00 p.m. PT on Tuesday, January 14.
Biotech Showcase 2025 Presentation Details:
Date: Tuesday, January 14, 2025
Time: 3:00 PM PT
Track: Yosemite-C
Webcast Link: HERE
Webcast Archive: HERE
Commenting on being selected to speak at the conference, Dr. Sinkule stated: “I am delighted to have the honor of presenting at this prestigious conference. I welcome the opportunity of sharing novel information about our company and the secreted form of the Klotho anti-aging gene, ’s-KL’, the patent protected development platform on which our product candidates are being developed for ALS, Alzheimer’s, and Parkinson’s disease.”
Dr. Sinkule continued: “It is apparent that, while there is a plethora of scientific literature about Klotho, it is still relatively unknown among many members of the global scientific community. At Klotho Neurosciences, we plan to expand the awareness of this intriguing ’master gene‘ and the role it may play in treating these devastating neurodegenerative diseases. In particular, we are working diligently towards entry into the clinic with ALS, and are actively seeking development partnerships with regard to Alzheimer’s and Parkinson’s, as well as a number of other age-related disorders.”
Klotho Neurosciences has secured an exclusive worldwide license from Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançats (ICREA) in Spain. As a result, Klotho Neurosciences has the exclusive use of patents issued in the USA, Europe, and China for its innovative therapeutic approach. The patents cover a secreted splice variant of mammalian Klotho, s-KL. as a treatment for cognitive and behavioral impairments.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biopharmaceutical company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the “anti-aging” human Klotho gene and its novel delivery system (s-KL/AAV.myo) to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company’s current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostics. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
For more information, contact:
Eric Boyd
Investor Relations
Email: IR@klothoneuro.com
Website: www.klothoneuro.com
Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s research and development plans, the potential efficacy and safety of the Company’s investigational therapies, anticipated timelines for preclinical studies and clinical trials, regulatory pathways, market opportunities, and the Company’s ability to advance its programs and achieve its strategic objectives. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, but not limited to, uncertainties inherent in preclinical research, the initiation, timing, and results of clinical trials, the Company’s ability to secure regulatory approvals, and the Company’s ability to secure financing to support its development programs. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
FAQ
When and where will Klotho Neurosciences (KLTO) present at Biotech Showcase 2025?
What diseases is KLTO developing treatments for?
What is the key technology platform KLTO is using for drug development?
Which territories are covered by KLTO's patents for s-KL treatment?
What partnerships is KLTO currently seeking?
From which institutions did KLTO secure their exclusive worldwide license?
